Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna Inc. (NASDAQ:MRNA) is developing mRNA-1769 as a mpox vaccine for use in adults.
Moderna Inc. (纳斯达克:MRNA)正在开发mRNA-1769作为成人mpox疫苗。
Currently, a Phase 1/2 trial evaluating the safety, tolerability, and immunogenicity of mRNA-1769 in Healthy Participants is underway. The 351-subject trial was started in 2023, and data is anticipated in 2025.
目前，一项评估健康参与者mRNA-1769的安全性、耐受性和免疫原性的1/2期试验正在进行中。这项351名受试者的试验于2023年开始，预计数据将在2025年公布。
In a paper released in Cell, Moderna's mRNA-1769 had been more effective than the Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) Jynneos vaccine in preventing severe disease and reducing virus levels in monkeys.
在Cell杂志上发表的一篇文章中，Moderna的mRNA-1769在防止猴子严重疾病和降低病毒水平方面比巴伐利亚诺德克公司（场外交易:BVNRY）（场外交易:BVNKF）的Jynneos疫苗更有效。
Also read: Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic.
还阅读: Mpox疫苗: 刚果在宣布疫情后近两年后收到第一批疫苗剂量，挑战仍然存在。
Jynneos is based on modified vaccinia Ankara (MVA).
Jynneos基于修饰后的天花病毒安卡拉（MVA）。
MVA immunization reduced lesions in challenged non-human primates (NHPs), but most MVA-immunized animals were still classified as experiencing "grave" disease (over 250 lesions) based on WHO lesion number classification. By contrast, none of the mRNA-immunized animals reached the criteria for "severe" disease (over 100 lesions) during the infection period.
MVA免疫可以减少挑战的非人类灵长类动物的病变，但大多数MVA免疫的动物仍被归类为“严重”疾病（超过250个病变），根据世卫组织病变数量分类。相比之下，在感染期间，没有一个mRNA免疫动物符合“严重”疾病（100个病变以上）的标准。
While MVA and mRNA-1769 conferred complete protection following lethal mpox infection challenge, mRNA-immunized animals experienced 10-fold fewer lesions, reduced disease duration, and substantial mitigation of circulating and mucosal viremia in the mRNA cohort.
虽然MVA和mRNA-1769在致命的mpox感染挑战后提供了完全保护，但mRNA免疫动物的病变减少了10倍，疾病持续时间缩短，并且在mRNA队列中循环和粘膜病毒血症得到了显著减轻。
The paper highlights that despite the effectiveness of the Jynneos vaccine against mpox, issues in supply, unfavorable reactogenicity, incomplete immunity, and uncertainty of cross-protection to more virulent strains provide critical motivation for the development of a potential new vaccine modality for improved vaccines to cover these gaps.
该论文强调，尽管Jynneos疫苗对付mpox很有效，但供应问题、不利的反应原性、不完全的免疫以及对更具侵略性的菌株的交叉保护的不确定性，为开发潜在的新疫苗模式提供了关键动力，以改善对这些缺口的疫苗。
BioNTech SE (NASDAQ:BNTX) is also developing an mRNA vaccine for mpox, BNT166a, which is also in Phase 1/2 study, with data readout expected in May 2025.
BioNTech SE (纳斯达克：BNTX)也正在开发一种mRNA生物-疫苗用于mpox疫苗，BNT166a，也处于1/2期研究阶段，预计在2025年5月公布数据。
Price Action: MRNA stock is down 1.39% at $72.42 at the last check on Friday.
价格走势：MRNA股票在上周五最后一次检查时下跌1.39%，至72.42美元。
- Robinhood Shifted From Meme Stock To Market Contender Amid New Products And Global Expansion: Analyst Upgrades Stock.
- 罗宾汉由热门股票转变为市场竞争对手，推出新产品和全球扩张：分析师将股票评级提升。
Photo by Lutsenko_Oleksandr on Shutterstock
Photo by Lutsenko_Oleksandr on shutterstock